These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 39294688

  • 1. Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study.
    Su Z, Zhang C, Gao C, Li C, Li R, Zheng Z.
    Arthritis Res Ther; 2024 Sep 18; 26(1):163. PubMed ID: 39294688
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
    Li H, Chen C, Yang H, Tu J.
    Eur J Pediatr; 2024 Sep 18; 183(9):3987-3995. PubMed ID: 38940925
    [Abstract] [Full Text] [Related]

  • 3. Belimumab in early systemic lupus erythematosus: A propensity score matching analysis.
    Lu C, He N, Dou L, Yu H, Li M, Leng X, Zeng X.
    Immun Inflamm Dis; 2024 Aug 18; 12(8):e1362. PubMed ID: 39172013
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study.
    Sun F, Wu H, Wang Z, Wu T, Wu X, Chen J, Zhang D, Bao C, Shen N, Wu L, Zhu J, Ye S.
    Biomedicines; 2023 Mar 21; 11(3):. PubMed ID: 36979944
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 21; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 6. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
    Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A, Katsimbri P, Theotikos E, Pitsigavdaki S, Pateromichelaki K, Bertsias A, Elezoglou A, Sidiropoulos P, Fanouriakis A, Boumpas D, Bertsias G.
    Front Immunol; 2022 Sep 21; 13():1074044. PubMed ID: 36685524
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
    Wang D, Shan C, Liu J, Zhang R, Zhu G, Gao T, Chang H, Gao S, Bai C, Nie N, Zhang Q, Lin Y.
    Front Immunol; 2022 Sep 21; 13():1067721. PubMed ID: 36591249
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May 21; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 9. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 21; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Belimumab for systemic lupus erythematosus.
    Singh JA, Shah NP, Mudano AS.
    Cochrane Database Syst Rev; 2021 Feb 25; 2(2):CD010668. PubMed ID: 33631841
    [Abstract] [Full Text] [Related]

  • 12. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar 25; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes in lupus nephritis patients treated with belimumab in real-life setting: a retrospective comparative study in China.
    Lin Z, Jiang B, Wang W, Chen C, Wang Y, Wan J, Xu Y.
    PeerJ; 2024 Mar 25; 12():e18028. PubMed ID: 39308826
    [Abstract] [Full Text] [Related]

  • 14. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 25; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
    Wang L, Liang X, Cao Z, Wang D, Luo Y, Feng Y, Luo C, Zhi S, Huang Y, Fan Z, Wang C, Liu H, Liu J, Zhang T, Cheng Q, Xie X, Shuai L, Rong Z, Zeng P, Yu H, Lu M, Sun L, Yang S, Zhao D, Zhang W, Wu X, Li Q, Wang Y, Zhang Q, Yang J, Li X, Song H, Tang X.
    Rheumatology (Oxford); 2024 May 02; 63(5):1437-1446. PubMed ID: 37606970
    [Abstract] [Full Text] [Related]

  • 16. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.
    Lupus; 2016 Dec 02; 25(14):1587-1596. PubMed ID: 27488472
    [Abstract] [Full Text] [Related]

  • 17. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C, Yang T, Zheng S, Liao X, Xie R, Chen S, Li J.
    Front Immunol; 2024 Dec 02; 15():1423035. PubMed ID: 38947321
    [Abstract] [Full Text] [Related]

  • 18. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 02; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 19. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug 02; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.